AIDS is a fatal disease with no effective treatment. An AIDS diagnosis is a death sentence.

From 1981 to the middle of 1996, a diagnosis of AIDS was understood, correctly, as a death sentence delivered in the vocabulary of medicine. The figures were not subtle. Between 1981 and 1995, AIDS killed more than 300,000 Americans. By 1994, it was the leading cause of death for men between the ages of 25 and 44 in the United States. The median survival after an AIDS diagnosis in the early years was measured in months; with improved management of opportunistic infections, survival could be extended to two or three years. Patients who were diagnosed counted their remaining time with a clarity that most people never achieve.

The first antiretroviral drug, zidovudine, AZT, was approved by the FDA in March 1987 following accelerated clinical trials. AZT blocked the reverse transcriptase enzyme HIV uses to copy its genetic material into the host cell's DNA. It extended survival by a modest margin. But HIV replicates at extraordinary speed and generates enormous genetic diversity through frequent copying errors. Within months of starting AZT, resistant variants emerged and the drug became ineffective. The pattern repeated with each new single-agent antiretroviral that entered clinical testing through the late 1980s and early 1990s. Each drug bought time. None bought cure.

The pathogenesis of HIV was not well understood until the mid-1990s, when David Ho and George Shaw led research that revealed the true scale of viral replication, billions of new viral copies each day, with the entire circulating virus population turning over roughly every two days. What had appeared to be a long latency period was revealed, by newly available quantitative PCR techniques, to be a period of ferocious ongoing viral activity in which the immune system and the virus were locked in an exhausting daily war of attrition. The implication for treatment was stark: any effective therapy would have to suppress viral replication to near zero and, to prevent resistance from emerging, would have to attack multiple steps in the replication cycle simultaneously.

By 1994 and 1995, two new drug classes had entered clinical testing: protease inhibitors and non-nucleoside reverse transcriptase inhibitors. When used individually, they followed the same trajectory as AZT, resistant variants emerged. Then researchers began combining drugs from different classes. Pilot data suggested that triple-drug combinations could suppress viral load to below the limit of detection in blood. Whether that suppression would hold, and whether it would translate into extended survival, remained an open question in early 1996.

The XI International AIDS Conference met in Vancouver, British Columbia, in July 1996. Sixteen thousand researchers, clinicians, and advocates attended. The headline finding, presented by David Ho and confirmed by independent clinical groups, was that triple-combination antiretroviral therapy, HAART, could reduce viral loads to undetectable levels in the majority of patients who achieved it. For the first time, clinicians stood before large audiences and used language previously absent from AIDS medicine: long-term remission, years of survival rather than months.

The year that followed was unlike any in the history of the epidemic. AIDS mortality in the United States, which had peaked at over 43,000 deaths in 1995, fell by nearly half within two years. Hospitalizations collapsed. Wards that had been full of patients dying of opportunistic infections emptied. Clinicians who had spent a decade managing the final stages of disease found themselves instead managing a chronic condition requiring a complex daily drug regimen.

Access was profoundly unequal. Triple therapy was expensive, costs ran to tens of thousands of dollars annually, and in sub-Saharan Africa, where the epidemic had its largest geographic footprint, the drugs remained largely inaccessible for a decade after Vancouver. The mortality transformation celebrated in North America and Western Europe did not reach the populations carrying the greatest burden of the disease until the early 2000s, when international funding and generic drug production reduced costs enough to permit wider distribution.

For students who graduated from American high schools between 1981 and 1996, AIDS had been presented throughout their schooling as an invariably fatal disease for which medicine had no answer. They had been taught the truth as it existed. What changed was not the teaching, but the science, over fifteen years of virological research and clinical trial, arriving at a stage in Vancouver in the summer of 1996.